TNF |
Conflicting data regarding elevated CSF levels in NPSLE
Treatment with TNF inhibitors can induce SLE-like symptoms
Increased levels can impair the BBB via increased local inflammation
|
115,211–214 |
BAFF |
Mediates B cell survival and promotes immunoglobulin class switching (important in SLE pathogenesis)
Anti-BAFF (belimumab) antibody treatment is approved for the treatment of SLE, but efficacy in NPSLE has not been established
|
215,216,189 |
IFNα |
Important in SLE pathogenesis
Strong systemic interferon signature in patients with NPSLE
Induced in vitro by CSF from patients with NPSLE
Activates microglia leading to synaptic pruning
Can induce depression (most common adverse effect), psychotic features, confusion, focal neurological deficits and seizures
|
149–151,217–219 |
TWEAK |
Mediates BBB disruption, choroid plexus cellular infiltration and neuronal damage
Elevated in the CSF of patients with SLE
|
49,156,220 |
IFNγ |
Mainly produced by T cells and found in high levels in sera from patients with SLE
Elevated in the CSF of patients with NPSLE, which can distinguish NPSLE from demyelinating neurological conditions
|
160 |
IL-6 |
Secreted primarily by myeloid cells, activated astrocytes and endothelial cells
Stimulates B cells, promotes immunoglobulin secretion by plasma cells, promotes differentiation of TH17 cells and inhibits differentiation of regulatory T cells
Elevated in the CSF of patients with NPSLE, but similarly elevated in CSF from patients with demyelinating neurological conditions and septic meningitis
|
152,160,211,221 |
IL-8 |
Secreted by several cell types, including activated endothelial cells
Elevated in the CSF of patients with NPSLE, but similarly elevated in CSF from patients with demyelinating neurological conditions and septic meningitis
|
152,160,211 |